Do analysts prefer FLNA or ZIVO?

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 257.14%. Given Cassava Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cassava Sciences is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is FLNA or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% ZIVO Bioscience N/A N/A -2,240.92%

Does the media prefer FLNA or ZIVO?

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.04 beat ZIVO Bioscience's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ZIVO or ACRV?

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 652.69%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is ZIVO or ACRV more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media refer more to ZIVO or ACRV?

In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.94 beat ZIVO Bioscience's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EDSA or ZIVO?

Edesa Biotech presently has a consensus target price of $5.00, indicating a potential downside of 29.48%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is EDSA or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer ZIVO or OTLK?

Oncobiologics has a consensus target price of $4.50, indicating a potential upside of 466.18%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts plainly believe Oncobiologics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oncobiologics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ZIVO or OTLK more profitable?

Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Oncobiologics N/A N/A -291.28%

Does the media prefer ZIVO or OTLK?

In the previous week, Oncobiologics had 8 more articles in the media than ZIVO Bioscience. MarketBeat recorded 9 mentions for Oncobiologics and 1 mentions for ZIVO Bioscience. Oncobiologics' average media sentiment score of 0.91 beat ZIVO Bioscience's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BYSI or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BYSI or ZIVO more profitable?

Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% ZIVO Bioscience N/A N/A -2,240.92%

Does the media refer more to BYSI or ZIVO?

In the previous week, BeyondSpring had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for BeyondSpring and 1 mentions for ZIVO Bioscience. BeyondSpring's average media sentiment score of 0.96 beat ZIVO Bioscience's score of 0.00 indicating that BeyondSpring is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeyondSpring 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ZIVO Bioscience (ZIVO) Competitors

$3.72 0.00 (0.00%)

As of 06/3/2026 03:44 PM Eastern

Compare

ZIVO vs. FLNA, ACRV, EDSA, OTLK, and BYSI

Should you buy ZIVO Bioscience stock or one of its competitors? MarketBeat compares ZIVO Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZIVO Bioscience include Cassava Sciences (FLNA), Acrivon Therapeutics (ACRV), Edesa Biotech (EDSA), Oncobiologics (OTLK), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does ZIVO Bioscience compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.04 beat ZIVO Bioscience's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ZIVO Bioscience's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
ZIVO Bioscience	N/A	N/A	-2,240.92%

ZIVO Bioscience has higher revenue and earnings than Cassava Sciences. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
ZIVO Bioscience	$15.85K	973.17	-$7.78M	-$1.71	N/A

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 257.14%. Given Cassava Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cassava Sciences is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cassava Sciences has a beta of -0.71, meaning that its share price is 171% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

Summary

Cassava Sciences beats ZIVO Bioscience on 7 of the 13 factors compared between the two stocks.

How does ZIVO Bioscience compare to Acrivon Therapeutics?

ZIVO Bioscience (NASDAQ:ZIVO) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.94 beat ZIVO Bioscience's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ZIVO Bioscience has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 652.69%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

ZIVO Bioscience's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

ZIVO Bioscience has higher revenue and earnings than Acrivon Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	973.17	-$7.78M	-$1.71	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Summary

Acrivon Therapeutics beats ZIVO Bioscience on 7 of the 13 factors compared between the two stocks.

How does ZIVO Bioscience compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, ZIVO Bioscience had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Edesa Biotech. ZIVO Bioscience's average media sentiment score of 0.00 beat Edesa Biotech's score of -0.52 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Negative
ZIVO Bioscience	Neutral

Edesa Biotech presently has a consensus target price of $5.00, indicating a potential downside of 29.48%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Edesa Biotech has higher earnings, but lower revenue than ZIVO Bioscience. Edesa Biotech is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
ZIVO Bioscience	$15.85K	973.17	-$7.78M	-$1.71	N/A

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ZIVO Bioscience's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Edesa Biotech has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

Summary

Edesa Biotech beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Oncobiologics?

ZIVO Bioscience (NASDAQ:ZIVO) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

ZIVO Bioscience has higher earnings, but lower revenue than Oncobiologics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	973.17	-$7.78M	-$1.71	N/A
Oncobiologics	$1.35M	82.45	-$62.42M	-$1.17	N/A

In the previous week, Oncobiologics had 8 more articles in the media than ZIVO Bioscience. MarketBeat recorded 9 mentions for Oncobiologics and 1 mentions for ZIVO Bioscience. Oncobiologics' average media sentiment score of 0.91 beat ZIVO Bioscience's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by insiders. Comparatively, 2.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ZIVO Bioscience has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Oncobiologics has a consensus target price of $4.50, indicating a potential upside of 466.18%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts plainly believe Oncobiologics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Oncobiologics	N/A	N/A	-291.28%

Summary

Oncobiologics beats ZIVO Bioscience on 10 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BeyondSpring has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

In the previous week, BeyondSpring had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for BeyondSpring and 1 mentions for ZIVO Bioscience. BeyondSpring's average media sentiment score of 0.96 beat ZIVO Bioscience's score of 0.00 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeyondSpring	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeyondSpring has higher revenue and earnings than ZIVO Bioscience. BeyondSpring is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	40.18	-$1.01M	-$0.14	N/A
ZIVO Bioscience	$15.85K	973.17	-$7.78M	-$1.71	N/A

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

BeyondSpring beats ZIVO Bioscience on 10 of the 12 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.43M	$349.70M	$6.30B	$12.43B
Dividend Yield	N/A	N/A	2.69%	5.33%
P/E Ratio	-0.76	N/A	24.03	24.35
Price / Sales	973.17	172.68	518.85	115.59
Price / Cash	N/A	22.44	41.39	55.53
Price / Book	-4.59	4.73	9.98	6.72
Net Income	-$7.78M	-$141.03M	$3.56B	$337.03M
7 Day Performance	-15.57%	-3.76%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-78.78%	64.64%	28.76%	33.98%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$3.72 flat	N/A	-78.8%	$15.43M	$15.85K	N/A	10	News Coverage Gap Up
FLNA Cassava Sciences	2.1158 of 5 stars	$1.55 +3.3%	$5.00 +222.6%	-37.0%	$72.46M	N/A	N/A	20	Gap Up
ACRV Acrivon Therapeutics	2.3157 of 5 stars	$1.63 -1.8%	$11.67 +615.7%	+30.2%	$71.05M	N/A	N/A	58	Analyst Upgrade
EDSA Edesa Biotech	1.9783 of 5 stars	$7.86 -1.4%	$5.00 -36.4%	+244.7%	$70.87M	N/A	N/A	20
OTLK Oncobiologics	3.6583 of 5 stars	$0.74 +26.4%	$4.50 +508.1%	-56.2%	$70.76M	$1.35M	N/A	20	News Coverage Insider Trade Options Volume Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. FLNA, ACRV, EDSA, OTLK, and BYSI

How does ZIVO Bioscience compare to Cassava Sciences?

Summary

How does ZIVO Bioscience compare to Acrivon Therapeutics?

Summary

How does ZIVO Bioscience compare to Edesa Biotech?

Summary

How does ZIVO Bioscience compare to Oncobiologics?

Summary

How does ZIVO Bioscience compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. FLNA, ACRV, EDSA, OTLK, and BYSI

How does ZIVO Bioscience compare to Cassava Sciences?

Does the media prefer FLNA or ZIVO?

Is FLNA or ZIVO more profitable?

Which has preferable valuation and earnings, FLNA or ZIVO?

Do analysts prefer FLNA or ZIVO?

Do institutionals and insiders have more ownership in FLNA or ZIVO?

Which has more risk & volatility, FLNA or ZIVO?

Summary

How does ZIVO Bioscience compare to Acrivon Therapeutics?

Do insiders and institutionals have more ownership in ZIVO or ACRV?

Does the media refer more to ZIVO or ACRV?

Which has more volatility and risk, ZIVO or ACRV?

Do analysts rate ZIVO or ACRV?

Is ZIVO or ACRV more profitable?

Which has stronger earnings & valuation, ZIVO or ACRV?

Summary

How does ZIVO Bioscience compare to Edesa Biotech?

Does the media prefer EDSA or ZIVO?

Do analysts rate EDSA or ZIVO?

Which has higher valuation and earnings, EDSA or ZIVO?

Do insiders & institutionals hold more shares of EDSA or ZIVO?

Is EDSA or ZIVO more profitable?

Which has more risk and volatility, EDSA or ZIVO?

Summary

How does ZIVO Bioscience compare to Oncobiologics?

Which has preferable valuation and earnings, ZIVO or OTLK?

Does the media prefer ZIVO or OTLK?

Do insiders & institutionals hold more shares of ZIVO or OTLK?

Which has more volatility and risk, ZIVO or OTLK?

Do analysts prefer ZIVO or OTLK?

Is ZIVO or OTLK more profitable?

Summary

How does ZIVO Bioscience compare to BeyondSpring?

Do analysts rate BYSI or ZIVO?

Do institutionals & insiders believe in BYSI or ZIVO?

Which has more volatility & risk, BYSI or ZIVO?

Does the media refer more to BYSI or ZIVO?

Which has preferable earnings and valuation, BYSI or ZIVO?

Is BYSI or ZIVO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools